Eli Lilly is investing more than $470 million to build a new pharmaceutical manufacturing facility in Durham, North Carolina.
The site will be a state-of-the-art facility that produces parenteral (or injectable) products and delivery devices.
To operate the site, Lilly will create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations.
The facility will fortify its seven existing manufacturing sites across the US in Indiana, New Jersey and Puerto Rico.
“This next-generation manufacturing facility will allow us to expand our capacity to make the Lilly medicines that are helping people with serious illnesses today, and help us prepare for new medicines coming from our robust pipeline in the future,” said Chairman and CEO David A. Ricks.
“In the past two years, we have invested billions of capital in new US-based manufacturing because the 2017 tax reform rebalanced the playing field in favour of the American worker.”